ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mazdutide

Also written as “IBI362”, “LY3305677” and “Mazdutide”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Overweight · Fatty Liver · Alcoholism, led by 2 companies.

Drug pageMazdutide: every studyAll 44 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 19, 202227 company-led studies, 9 open or runningLicense: Lilly → Innovent, Aug 2019Next primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologicsits history only208 open or runningphase 3since Oct 19, 2022Jun 5, 2020Dec 31, 2026phase 3 · NCT06884293
Eli Lilly71 open or runningphase 2since Nov 6, 2023Nov 21, 2016Sep 2027phase 2 · NCT06143956

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 21, 2016First study: phase 1 study in HealthyFirst studyNCT02972645 · 66 enrolled · United Kingdom
  2. Oct 26, 2017Phase 1 study in HealthyNCT03325387 · 56 enrolled · United Kingdom
  3. Apr 24, 2019Phase 1 study in Diabetes Mellitus, Type 2NCT03928379 · 24 enrolled · Germany
  4. Aug 21, 2019Innovent licensed it from LillyLicenseChina · announced · Innovent (release)
  5. Jan 25, 2022Named mazdutideINNProposed as its International Nonproprietary Name in WHO's List 126 · before, IBI362, LY3305677
  6. Nov 15, 2022Phase 1 study in OverweightNCT05623839 · 32 enrolled · United States
  7. Nov 6, 20232 phase 2 studies in ObesityNCT06143956, NCT06124807
  8. Feb 5, 2025Phase 2 study in AlcoholismNCT06817356 · 308 enrolled · United States

Ahead

  1. Sep 2027Primary completion: phase 2 study in ObesityNCT06143956

TargetBeta

GLP1R →read by rule
“Mazdutide is a synthetic peptide analog of mammalian oxyntomodulin and a once-weekly dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), under development for the treatment of obesity and type 2 diabetes (T2D).”study text, by rule · the study

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
zenagamtideNovo Nordiskphase 336
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
brenipatideEli Lillyphase 319
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 7 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06817356Alcoholism · United States2CompletedMar 19, 2026308
NCT06143956Obesity · United States, Argentina2RecruitingSep 20271,481
NCT06124807Obesity · United States2CompletedJan 22, 2025179
NCT05623839Overweight · United States1CompletedJun 27, 202332
NCT03928379Diabetes Mellitus, Type 2 · Germany1CompletedJul 8, 202124
NCT03325387Healthy · United Kingdom1CompletedAug 3, 201856
NCT02972645Healthy · United Kingdom1CompletedJul 14, 201766

How it is read

Names in the registry

  • “IBI362”, 19 entries
  • “LY3305677”, 5 entries
  • “Mazdutide”, 2 entries
  • “IBI362 liquid formulation”, 1 entry
  • “IBI362 lyophilized powder”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.